Comments on: Atamyo Therapeutics Obtains US FDA Fast Track Designation for ATA-100, a Gene Therapy in Phase 1/2 Clinical Trials for Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9)

Comments on: Atamyo Therapeutics Obtains US FDA Fast Track Designation for ATA-100, a Gene Therapy in Phase 1/2 Clinical Trials for Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) https://atamyo.com/press-releases/atamyo-therapeutics-obtains-us-fda-fast-track-designation-for-ata-100-a-gene-therapy-in-phase-1-2-clinical-trials-for-limb-girdle-muscular-dystrophy-type-r9-lgmd-r9/ Changing life of Neuromuscular patients Tue, 10 Feb 2026 16:34:24 +0000 hourly 1 https://wordpress.org/?v=6.7.5